Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Combined Trial Reviews To Become The Norm In UK From 2022

Executive Summary

Having gained enough experience with the combined ethics and regulatory review of clinical trial applications, the UK will make this its only route for evaluating new drug trial applications starting next year.

You may also be interested in...



UK Supports End-To-End Management Of Trials Undergoing Combined Reviews

Ongoing efforts by the UK to deliver a single decision on the ethical and regulatory approval of new clinical trial applications have reached a major milestone ahead of the 2022 mandatory deadline. 

UK Regulator To Lose 20% Of Staff In Post-Brexit Cost-Cutting Plans

The MHRA intends to drop around 300 roles as it faces a financial crunch after leaving the EU and other pressures.

UK Focuses On Recovering Non-COVID-19 Research

The UK government has set aside over £64m ($89m) to support the first phase of activities to be undertaken in the coming months under a two-part initiative to strengthen clinical research delivery.

Related Content

Topics

UsernamePublicRestriction

Register

PS144449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel